Can Intermittent Dosing Optimize Prolonged Linezolid Treatment of Difficult Multidrug-Resistant Tuberculosis?

被引:40
作者
Chang, Kwok-Chiu [1 ]
Yew, Wing-Wai [2 ]
Cheung, Siu-Wai [3 ]
Leung, Chi-Chiu [1 ]
Tam, Cheuk-Ming [1 ]
Chau, Chi-Hung [4 ]
Wen, Peter Kin-Ho [4 ]
Chan, Raphael Chiu-Yeung [2 ]
机构
[1] Dept Hlth, TB & Chest Serv, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China
[4] Grantham Hosp, TB & Chest Unit, Hong Kong, Hong Kong, Peoples R China
关键词
MYCOBACTERIUM-TUBERCULOSIS; PHARMACOKINETICS; PNU-100480; ASSAY; SERUM;
D O I
10.1128/AAC.00388-13
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until >= 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.
引用
收藏
页码:3445 / 3449
页数:5
相关论文
共 21 条
[1]
Bailey EM, 2001, AM J KIDNEY DIS, V38, part. no.
[2]
Peripheral neuropathy associated with prolonged use of linezolid [J].
Bressler, AM ;
Zimmer, SM ;
Gilmore, JL ;
Somani, J .
LANCET INFECTIOUS DISEASES, 2004, 4 (08) :528-531
[3]
Intrapulmonary pharmacokinetics of linezolid [J].
Conte, JE ;
Golden, JA ;
Kipps, J ;
Zurlinden, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1475-1480
[4]
Hematologic effects of linezolid: Summary of clinical experience [J].
Gerson, SL ;
Kaplan, SL ;
Bruss, JB ;
Le, V ;
Arellano, FM ;
Hafkin, B ;
Kuter, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2723-2726
[5]
Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients [J].
Koh, Won-Jung ;
Kang, Yeh Rim ;
Jeon, Kyeonman ;
Kwon, O. Jung ;
Lyu, Jiwon ;
Kim, Woo Sung ;
Shim, Tae Sun .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) :1503-1507
[6]
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis [J].
Koh, Won-Jung ;
Kwon, O. Jung ;
Gwak, Hyesun ;
Chung, Joo Won ;
Cho, Sang-Nae ;
Kim, Woo Sung ;
Shim, Tae Sun .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :388-391
[7]
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis [J].
Lee, Myungsun ;
Lee, Jongseok ;
Carroll, Matthew W. ;
Choi, Hongjo ;
Min, Seonyeong ;
Song, Taeksun ;
Via, Laura E. ;
Goldfeder, Lisa C. ;
Kang, Eunhwa ;
Jin, Boyoung ;
Park, Hyeeun ;
Kwak, Hyunkyung ;
Kim, Hyunchul ;
Jeon, Han-Seung ;
Jeong, Ina ;
Joh, Joon Sung ;
Chen, Ray Y. ;
Olivier, Kenneth N. ;
Shaw, Pamela A. ;
Follmann, Dean ;
Song, Sun Dae ;
Lee, Jong-Koo ;
Lee, Dukhyoung ;
Kim, Cheon Tae ;
Dartois, Veronique ;
Park, Seung-Kyu ;
Cho, Sang-Nae ;
Barry, Clifton E., III .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (16) :1508-1518
[8]
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement [J].
Lovering, AM ;
Zhang, J ;
Bannister, GC ;
Lankester, BJA ;
Brown, JHM ;
Narendra, G ;
MacGowan, AP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (01) :73-77
[9]
Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones [J].
McKee, EE ;
Ferguson, M ;
Bentley, AT ;
Marks, TA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2042-2049
[10]
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections [J].
Nuermberger, E ;
Grosset, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (04) :243-255